Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression

J J Maller; K Broadhouse; A J Rush; E Gordon; S Koslow; S M Grieve

doi:10.1038/mp.2017.224

Back

Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression

Journal article

Peer reviewed

Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression

J J Maller, K Broadhouse, A J Rush, E Gordon, S Koslow and S M Grieve

Molecular psychiatry, Vol.23(8), pp.1737-1744

08/01/2018

DOI: 10.1038/mp.2017.224

PMID: 29133948

View Online

Abstract

Studies of patients with major depressive disorder (MDD) have consistently reported reduced hippocampal volumes; however, the exact pattern of these volume changes in specific anatomical subfields and their functional significance is unclear. We sought to clarify the relationship between hippocampal tail volumes and (i) a diagnosis of MDD, and (ii) clinical remission to anti-depressant medications (ADMs). Outpatients with nonpsychotic MDD (n=202) based on DSM-IV criteria and a 17-item Hamilton Rating Scale for Depression (HRSD ) score ⩾16 underwent pretreatment magnetic resonance imaging as part of the international Study to Predict Optimized Treatment for Depression (iSPOT-D). Gender-matched healthy controls (n=68) also underwent MRI scanning. An automated pipeline was used to objectively measure hippocampal subfield and whole brain volumes. Remission was defined as an HRSD of ⩽7 following 8 weeks of randomized open-label treatment ADMs: escitalopram, sertraline or venlafaxine-extended release. After controlling for age and total brain volume, hippocampal tail volume was larger in the MDD cohort compared to control subjects. Larger hippocampal tail volume was positively related to clinical remission, independent of total hippocampal volume, total brain volume and age. These data provide convergent evidence of the importance of the hippocampus in the development or treatment of MDD. Hippocampal tail volume is proposed as a potentially useful biomarker of sensitivity to ADM treatment.

Adult

Age Factors

Antidepressive Agents - therapeutic use

Citalopram - therapeutic use

Cohort Studies

Delayed-Action Preparations

Depressive Disorder, Major - diagnostic imaging

Depressive Disorder, Major - drug therapy

Depressive Disorder, Major - pathology

Depressive Disorder, Treatment-Resistant - diagnostic imaging

Depressive Disorder, Treatment-Resistant - drug therapy

Depressive Disorder, Treatment-Resistant - pathology

Female

Hippocampus - diagnostic imaging

Hippocampus - drug effects

Hippocampus - pathology

Humans

Image Interpretation, Computer-Assisted

Magnetic Resonance Imaging

Male

Organ Size

Pattern Recognition, Automated

Prognosis

Psychiatric Status Rating Scales

Remission Induction

Sertraline - therapeutic use

Venlafaxine Hydrochloride - therapeutic use

Details

Title: Subtitle: Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression
Creators: J J Maller - The Heart Research Institute
K Broadhouse - The Heart Research Institute
A J Rush - National University of Singapore
E Gordon - Brain Resource Ltd, San Francisco, CA, USA
S Koslow - University of Miami
S M Grieve - The University of Sydney
Resource Type: Journal article
Publication Details: Molecular psychiatry, Vol.23(8), pp.1737-1744
DOI: 10.1038/mp.2017.224
PMID: 29133948
NLM abbreviation: Mol Psychiatry
ISSN: 1359-4184
eISSN: 1476-5578
Language: English
Date published: 08/01/2018
Academic Unit: Radiology
Record Identifier: 9984848508002771

Metrics

2 Record Views

See more details